ClinConnect ClinConnect Logo
Search / Trial NCT03233087

Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study

Launched by BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES · Jul 26, 2017

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The DPANDA Study is a research trial focused on improving how doctors diagnose and understand the prognosis of aortic aneurysms and aortic dissections. These conditions involve the blood vessels connected to the heart, where an aneurysm is a bulge in the vessel wall, and dissection is when the wall tears. The study aims to find specific blood markers that can help identify these issues and predict how they might progress over time.

If you or a family member is between the ages of 65 and 74 and has been referred for evaluation of aortic dissection, you might be eligible to participate. Participants will be asked to provide blood samples and share their medical history. The study is currently recruiting patients, and it’s important to know that certain individuals, such as those with recent blood transfusions or other serious health conditions, may not qualify. Joining this study could help advance knowledge about these serious conditions and potentially improve future care for patients with similar issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Retrospective
  • All patients who were referred to the surgical service for evaluation and management of aortic dissection were included.
  • Perspective
  • Patients with initial suspicion of having AAD were perspectively enrolled.
  • Exclusion Criteria:
  • Retrospective
  • Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;
  • Patients with aortic trauma, pseudo aneurysm, history of heart failure, renal dysfunction, severe pulmonary diseases, or active cancer;
  • Patients who entered the hospital for checkups after surgery.
  • Perspective
  • Patients in whom there is little or no suspicion of a life-threatening disease;
  • Patients with confirmed acute myocardial infarction,angina or pulmonary embolism
  • The symptoms were clearly not related to AD (e.g. pleurisy, pneumonia, acute abdominal diseases).

About Beijing Institute Of Heart, Lung And Blood Vessel Diseases

The Beijing Institute of Heart, Lung and Blood Vessel Diseases is a leading clinical research organization dedicated to advancing the understanding and treatment of cardiovascular, pulmonary, and hematological conditions. Committed to innovative research and high-quality clinical trials, the Institute collaborates with national and international stakeholders to develop and evaluate novel therapeutic interventions. With a multidisciplinary team of experts, the Institute aims to improve patient outcomes through rigorous scientific inquiry and the translation of research findings into clinical practice. Its focus on patient-centered care and commitment to excellence positions it as a pivotal player in the field of cardiovascular and pulmonary health research.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials